Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. / Pedersen, Jannie; LaCasse, Eric C; Seidelin, Jakob B; Coskun, Mehmet; Nielsen, Ole H.

I: Trends in Molecular Medicine, Bind 20, Nr. 11, 11.2014, s. 652-65.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Pedersen, J, LaCasse, EC, Seidelin, JB, Coskun, M & Nielsen, OH 2014, 'Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation', Trends in Molecular Medicine, bind 20, nr. 11, s. 652-65. https://doi.org/10.1016/j.molmed.2014.09.006

APA

Pedersen, J., LaCasse, E. C., Seidelin, J. B., Coskun, M., & Nielsen, O. H. (2014). Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends in Molecular Medicine, 20(11), 652-65. https://doi.org/10.1016/j.molmed.2014.09.006

Vancouver

Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends in Molecular Medicine. 2014 nov.;20(11):652-65. https://doi.org/10.1016/j.molmed.2014.09.006

Author

Pedersen, Jannie ; LaCasse, Eric C ; Seidelin, Jakob B ; Coskun, Mehmet ; Nielsen, Ole H. / Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. I: Trends in Molecular Medicine. 2014 ; Bind 20, Nr. 11. s. 652-65.

Bibtex

@article{a6909e94d1f94997ba26b154c4d32473,

title = "Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation",

abstract = "The inhibitor of apoptosis (IAP) family members, notably cIAP1, cIAP2, and XIAP, are critical and universal regulators of tumor necrosis factor (TNF) mediated survival, inflammatory, and death signaling pathways. Furthermore, IAPs mediate the signaling of nucleotide-binding oligomerization domain (NOD)1/NOD2 and other intracellular NOD-like receptors in response to bacterial pathogens. These pathways are important to the pathogenesis and treatment of inflammatory bowel disease (IBD). Inactivating mutations in the X-chromosome-linked IAP (XIAP) gene causes an immunodeficiency syndrome, X-linked lymphoproliferative disease type 2 (XLP2), in which 20% of patients develop severe intestinal inflammation. In addition, 4% of males with early-onset IBD also have inactivating mutations in XIAP. Therefore, the IAPs play a greater role in gut homeostasis, immunity and IBD development than previously suspected, and may have therapeutic potential.",

author = "Jannie Pedersen and LaCasse, {Eric C} and Seidelin, {Jakob B} and Mehmet Coskun and Nielsen, {Ole H}",

year = "2014",

month = nov,

doi = "10.1016/j.molmed.2014.09.006",

language = "English",

volume = "20",

pages = "652--65",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd. * Trends Journals",

number = "11",

}

RIS

TY - JOUR

T1 - Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation

AU - Pedersen, Jannie

AU - LaCasse, Eric C

AU - Seidelin, Jakob B

AU - Coskun, Mehmet

AU - Nielsen, Ole H

PY - 2014/11

Y1 - 2014/11

N2 - The inhibitor of apoptosis (IAP) family members, notably cIAP1, cIAP2, and XIAP, are critical and universal regulators of tumor necrosis factor (TNF) mediated survival, inflammatory, and death signaling pathways. Furthermore, IAPs mediate the signaling of nucleotide-binding oligomerization domain (NOD)1/NOD2 and other intracellular NOD-like receptors in response to bacterial pathogens. These pathways are important to the pathogenesis and treatment of inflammatory bowel disease (IBD). Inactivating mutations in the X-chromosome-linked IAP (XIAP) gene causes an immunodeficiency syndrome, X-linked lymphoproliferative disease type 2 (XLP2), in which 20% of patients develop severe intestinal inflammation. In addition, 4% of males with early-onset IBD also have inactivating mutations in XIAP. Therefore, the IAPs play a greater role in gut homeostasis, immunity and IBD development than previously suspected, and may have therapeutic potential.

AB - The inhibitor of apoptosis (IAP) family members, notably cIAP1, cIAP2, and XIAP, are critical and universal regulators of tumor necrosis factor (TNF) mediated survival, inflammatory, and death signaling pathways. Furthermore, IAPs mediate the signaling of nucleotide-binding oligomerization domain (NOD)1/NOD2 and other intracellular NOD-like receptors in response to bacterial pathogens. These pathways are important to the pathogenesis and treatment of inflammatory bowel disease (IBD). Inactivating mutations in the X-chromosome-linked IAP (XIAP) gene causes an immunodeficiency syndrome, X-linked lymphoproliferative disease type 2 (XLP2), in which 20% of patients develop severe intestinal inflammation. In addition, 4% of males with early-onset IBD also have inactivating mutations in XIAP. Therefore, the IAPs play a greater role in gut homeostasis, immunity and IBD development than previously suspected, and may have therapeutic potential.

U2 - 10.1016/j.molmed.2014.09.006

DO - 10.1016/j.molmed.2014.09.006

M3 - Journal article

C2 - 25282548

VL - 20

SP - 652

EP - 665

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 11

ER -

ID: 135224691